This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2023 Mar 10;41(8):1630.

doi: 10.1200/JCO.22.01961. Epub 2023 Jan 6.

Triple-Negative Receptor Conversion at Metastatic Sites Might Show Better Efficacy in Patients Who Received Sacituzumab Govitecan

Kadri Altundag¹

Affiliations

PMID: 36608300
DOI: 10.1200/JCO.22.01961

Comment

Triple-Negative Receptor Conversion at Metastatic Sites Might Show Better Efficacy in Patients Who Received Sacituzumab Govitecan

Kadri Altundag. J Clin Oncol. 2023.

. 2023 Mar 10;41(8):1630.

doi: 10.1200/JCO.22.01961. Epub 2023 Jan 6.

Author

Kadri Altundag¹

Affiliation

¹ Kadri Altundag, MD, MKA Breast Cancer Clinic, Tepe Prime, Ankara, Turkey.

PMID: 36608300
DOI: 10.1200/JCO.22.01961

No abstract available

PubMed Disclaimer

Comment on

Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
Rugo HS, Bardia A, Marmé F, Cortes J, Schmid P, Loirat D, Trédan O, Ciruelos E, Dalenc F, Pardo PG, Jhaveri KL, Delaney R, Fu O, Lin L, Verret W, Tolaney SM. Rugo HS, et al. J Clin Oncol. 2022 Oct 10;40(29):3365-3376. doi: 10.1200/JCO.22.01002. Epub 2022 Aug 26. J Clin Oncol. 2022. PMID: 36027558 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.